• 1
    McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. IJIR 2000; 12: S6S11
  • 2
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 5461
  • 3
    Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 1216
  • 4
    Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 13326
  • 5
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 82230
  • 6
    Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60: 1227
  • 7
    Saenz d, TI, Knight JR, Anglin G, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 215964
  • 8
    Montorsi F, McCullough A, Brock G et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy. IJIR 2003; 15: S1701
  • 9
    Padma-Nathan H, Rosen RC, Shabsigh R, Saikali K, Watkins V. Tadalafil (IC351) provides prompt and extended period of response for the treatment of men with ED. IJIR 2001; 13: S64
  • 10
    Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, Tseng L-J, De Riesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003; 62: 4003
  • 11
    Hellstrom WJG. Vardenafil: a new approach to the treatment of erectile dysfunction. Curr Urol Rep 2003; 4: 47987
  • 12
    Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). IJIR 2001; 13: S43
  • 13
    Muirhead GJ, Allen MJ, James CG et al. Pharmacokinetics of sildenafil (Viagra), a selective cGMP PDE5 inhibitor, after single oral doses in fasted and fed healthy volunteers. Br J Clin Pharmacol 1996; 42: 268
  • 14
    Jetter A, Kinzig-Schippers M, Walchner-Bonjean M et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002; 71: 219
  • 15
    Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43: 2607
  • 16
    Montorsi F, Verheyden B, Meuleman E et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 33945
  • 17
    Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002; 4 (Suppl): H32H47
  • 18
    Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92: 3746
  • 19
    Hellstrom WJG, Overstreet JW, Yu A et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170: 8871